Friday’s Highlights at Noon: Rosetta Genomics Ltd (ROSG), Acura Pharmaceuticals (ACUR), Vale SA (VALE), Titan Pharmaceuticals (TTNP), Athersys (ATHX)

By Carrie Williams

So far Friday, January 25, NASDAQ is up 1.27% and the S&P is up 0.49%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Rosetta Genomics Ltd (ROSGResearch Report), Acura Pharmaceuticals (ACURResearch Report), Vale SA (VALEResearch Report), Titan Pharmaceuticals (TTNPResearch Report) and Athersys (ATHXResearch Report).

Rosetta Genomics Ltd is down -55.56% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

Acura Pharmaceuticals is up 52.67% in midday trading to $0.20. Shares opened today at $0.13. The company has a 52-week low of $0.06 and a 52-week high of $0.00.

Vale SA is down -11.53% in midday trading to $13.43. Shares opened today at $15.18. The company has a 52-week low of $11.93 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $15.63, marking a 2.96% potential upside from current levels. In a report issued on January 10, Barclays analyst Amos Fletcher maintained a Buy rating on VALE, with a price target of $16.25, which implies an upside of 7% from current levels. Separately, on October 30, Citigroup’s Alexander Hacking downgraded the stock to Hold .

See today’s analyst top recommended stocks >>

Titan Pharmaceuticals is down -10.14% in midday trading to $1.24. Shares opened today at $1.38. The company has a 52-week low of $1.03 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Athersys is up 8.07% in midday trading to $1.74. Shares opened today at $1.61. The company has a 52-week low of $1.29 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $8.00, marking a 396.89% potential upside from current levels. In a report issued on January 23, Maxim Group analyst Jason McCarthy maintained a Buy rating on ATHX, with a price target of $8, which represents a potential upside of 397% from where the stock is currently trading.

Trending Stocks Based on Insider Activity >>